Our Firm is representing a number of clients in Lipitor lawsuits that put forth allegations similar to those included in these complaints. We are pleased to see these cases moving forward.
New York, New York (PRWEB) February 05, 2015
The federal court overseeing hundreds of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com) that claim the statin medication increases the risk that patients will develop Type 2 diabetes has denied Pfizer, Inc.’s motion seeking dismissal of 10 claims filed on behalf of Texas plaintiffs, Bernstein Liebhard LLP reports. According to an Order issued in the U.S. District Court, District of South Carolina on February 2nd, the Court rejected Pfizer’s contention that the plaintiffs’ failure-to-warn claims were preempted by federal law. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is representing a number of clients in Lipitor lawsuits that put forth allegations similar to those included in these complaints. We are pleased to see these cases moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Court documents indicate that more than 1,600 Lipitor diabetes claims are currently pending in the U.S. District Court, District of South Carolina. All of the lawsuits accuse Pfizer Inc. of concealing the drug’s association with diabetes in order to protect its profits from Lipitor. The claims further allege that information added to the Lipitor label in 2012 regarding its impact on blood sugar levels were not sufficient to warn users about its link to the disorder. Finally, plaintiffs assert that they would not have used Lipitor, or would have been more closely monitored for diabetes, had Pfizer’s warnings been adequate.
According to court records, the litigation involving Lipitor and diabetes has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) announced that the labels for Lipitor and other statins would be updated to include new information about their potential association with Type 2 diabetes. The label change was prompted by the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *
Lipitor patients who allegedly developed Type 2 diabetes due to the medication may be entitled to compensation from Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com